secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECIGEN, INC. (PGEN)
CIK:        0001356090
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0000950103-24-000379
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precigen announces PRGN-2012 Phase 2 data expected Q2 2024; BLA submission planned H2 2024
--------------------------------------------------------------------------------

- PRGN-2012 Phase 2 pivotal data in RRP anticipated Q2 2024; BLA submission under accelerated approval H2 2024.
- Commercial readiness preparations underway for potential PRGN-2012 launch in 2025.
- PRGN-2009 Phase 2 study in OPSCC enrolling; cervical cancer trial to start Q1 2024.
- PRGN-3006 Phase 1b dose expansion interim data expected H2 2024; Phase 1 showed 27% ORR in r/r AML.
- New CD19 UltraCAR-T preclinical data presented; Phase 1 study preparation underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356090/000095010324000379/0000950103-24-000379-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356090/000095010324000379/dp205018_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-24-000379

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer